NIDA Research Monograph, Number 131 [Printed in 1993]
If you have the Acrobat reader plug-in for Netscape or Internet Explorer click on the document link and you will be able
to view and/or print out the pages. If you have trouble viewing the document in your browser window, download the document (Windows users - right click on the link and Save as...) to your computer and get Adobe Acrobat Reader (free) in order to view it.
This monograph is not available by chapter. The Table of Contents (below) is shown to assist in locating information prior to downloading the monograph.
Download Monograph131.pdf - Impact of Prescription Drug Diversion Control
Systems on Medical Practice and Patient Care (2.1 MB)
Table of Contents
Preface-----iii
The Impact of Prescription Drug Control Systems on Medical Practice and Patient Care: A Summary of the NIDA Technical Review-----1
Guiding Principles of International and Federal Laws Pertaining to Medical Use and Diversion of Controlled Substances-----18
David E. Joranson
Session: Medical Use, Therapeutic Rationale-Prescribing and Control Issues
Therapeutic Use of Opioids: Prescribing and Control Issues-----35
Russell K. Portenoy
Anxiolytics: Indications, Benefits, and Risks of Short, and Long-Term Benzodiazepine Therapy Current Research Data-----51
Karl Rickels and Edward Schweizer
Issues and Controversies Regarding Benzodiazepine Use-----68
Carl Salzman
Stimulant Drugs-Medical Needs, Alternative Indications and Related Problems-----89
Jonathan O. Cole, Lenore A. BolIing, and Barbara J. Peake
Session: Abuse and Diversion
The Nonmedical Use of Prescription Drugs in the United States-----109
Edgar H. Adams and Andrva Kopstein
Drug Diversion Control Systems, Medical Practice, and Patient Care-----120
Gene R. Haislip
Session: Diversion Control Methods
Existing Methods to Identify Retail Drug Diversion-----132
G. Thomas Gitchel
PADS Approach to Preventing Prescription Drug Diversion-----141
John J. Ambre
Diversion Investigation Units-Methods, Utilities, and Limitations-----145
R. Keith Bulla
OSTAR-Oklahoma Schedule Two Abuse Reduction: An Electronic Point of Sale Diversion Control System-----151
Elaine Dodd
The Illinois Experience in Achieving the Medical/Regulatory Balance Required to Control Prescription Drug Diversion-----159
Mark T. Bishop and Ronald J. Vlasty
New York State's Triplicate Prescription Program-----176
John L. Eadie
Triplicate Prescriptions in Washington State-----194
Donald H. Williams
The Medicaid Prescription Drug Initiative-----200
Thomas Roslewicz
Summary and Conclusions of a Review of Prescription Drug Diversion Control Methods-----206
Constance Horgan, Jeffrey Prottas, Christopher Tompkins, Linda Wastila, and Melissa Bowden
Session: Impact on Medical Practice and Patient Care
Professional Association Responses
An American Medical Association Perspective on Preventing Prescription Drug Diversion-----224
John J. Ambre
Prescription Drug Regulation: Implications for Nursing and Health Care Delivery-Response of the American Nurses' Association-----228
Madeline A. Naegle
Perspective of the American Pharmaceutical Association-----235
C. Edwin Webb
Perspective of the Empire State Medical Association of the National Medical Association-----239
Gerald Deas
Prescribing Practices and Drug Abuse-Perspective of the American Society of Addiction Medicine . . . . . . . . . . . . . . . . . . . 242
Anne Geller
Response of the American Academy of Child and Adolescent Psychiatry-----246
Nicholas Rock
Advocacy Groups
Impact of Drug Regulation and Diversion Control System on Legitimate Narcolepsy Patients Response of American Narcolepsy Association-----249
Joseph A. Piscopo
State Cancer Pain Initiatives-----260
June L. Dahl
Benzodiazepine Dependence-A Treatment Program Perspective-----266
Robert D. O'Connor
A Public Citizen Health Research Group Perspective on Federal Triplicate Prescription Requirements for Controlled Substance Prescription Drugs-----270
Sidney Wolfe
Session: Evaluation of the Impact on Medical Practice and Medical Care
Consequences of the 1989 New York State Triplicate Benzodiazepine Prescription Regulations-----279
Michael Weintraub, Satesh Singh, Louise Byrne, Kumar Maharaj, and Laurence Guttmacher
Changes in Prescribing Patterns in Long-Term Care Facilities and Impact on Incidence of Adverse Events-----294
Sergio I. Zullich, Thaddeus H. Grasela, Jill B. Fiedler-Kelley, and Francis M. Gengo
Future Research Directions
A Research Agenda for Prescription Drug Diversion Control-----309
Constance Horgan, Jeffrey Prottas, Christopher Tompkins, Linda Wastila, and Melissa Bowden
The Impact of Prescription Drug Control Systems on Medical Practice and Patient Care-A Summary of Research Recommendations-----325
Dorynne Czechowicz
Appendix
List of May 30-June 1, 1991 Technical Review Participants-----331
List of October 3-4, 1991 Research Advisory Panel Participants-----334
|